The Enzyme Nobody Is Talking About in Chronic Gut Dysfunction

Why SIRT3 may be the missing link between mitochondrial failure, dysbiosis, and treatment resistance.

If you’ve been dealing with chronic gut issues — SIBO, IBS, dysbiosis, food intolerances that never resolve — you’ve probably heard about the microbiome, leaky gut, maybe even butyrate. But almost nobody in the gut health space is talking about SIRT3.

They should be. Because SIRT3 may be the single most important enzyme determining whether your colonocytes can function — and whether your gut ecology can recover.

What is SIRT3?

SIRT3 is a mitochondrial sirtuin — a NAD⁺-dependent deacetylase that lives inside the mitochondria of your cells. Think of it as the quality control manager of your cellular power plant. It doesn’t produce energy directly. It keeps the machinery that produces energy running properly.

SIRT3 does this by removing acetyl groups from key mitochondrial proteins. When proteins inside the mitochondria become hyperacetylated — meaning they accumulate too many acetyl tags — they lose function. They slow down. They malfunction. SIRT3 strips those tags off and restores activity.

Without adequate SIRT3 activity, your mitochondria accumulate damaged, sluggish proteins — and energy production collapses from the inside.

Why SIRT3 matters specifically in the gut

Your colonocytes — the epithelial cells lining your colon — are among the most mitochondrially dependent cells in your body. They derive roughly 70% of their energy from beta-oxidation of butyrate, a short-chain fatty acid produced by your gut bacteria. That process runs entirely through the mitochondria: beta-oxidation, the TCA cycle, and the electron transport chain.

Here’s what SIRT3 directly controls in that process:

Electron Transport Chain — Complex I and II. SIRT3 deacetylates and activates subunits of Complex I (NDUFA9) and Complex II (SDHA — succinate dehydrogenase). These are the entry points for electrons into the chain. When SIRT3 is low, Complex I and II activity drops. Electron flow slows. ATP output falls. But it gets worse — stalled electrons leak from the chain and react with oxygen to form superoxide. So low SIRT3 doesn’t just mean less energy. It means more oxidative damage to the very organelle that’s already failing.

SOD2 — Your mitochondrial antioxidant defense. SIRT3 deacetylates and activates manganese superoxide dismutase (SOD2), the primary enzyme that neutralizes superoxide inside the mitochondria. When SIRT3 drops, SOD2 stays acetylated, stays inactive, and superoxide accumulates unchecked. This creates a vicious cycle: low SIRT3 → more superoxide production from stalled ETC → less SOD2 to clear it → mitochondrial DNA damage → further decline in ETC protein expression → deeper energy failure.

The TCA cycle. SIRT3 activates isocitrate dehydrogenase 2 (IDH2) and glutamate dehydrogenase (GDH), both critical for TCA cycle flux and NADPH regeneration. NADPH is what your mitochondria use to recycle glutathione — your master antioxidant. So when SIRT3 drops, you lose both energy production AND antioxidant defense simultaneously.

Fatty acid oxidation. SIRT3 deacetylates long-chain acyl-CoA dehydrogenase (LCAD), a key enzyme in the beta-oxidation pathway. In colonocytes, this directly governs the ability to burn butyrate. Low SIRT3 = impaired butyrate oxidation = the colonocyte can’t use its primary fuel.

The SIRT3–NAD⁺ connection — and why it breaks

Here’s the critical piece: SIRT3 is completely dependent on NAD⁺ to function. It literally cannot work without it. NAD⁺ isn’t just a cofactor — it’s a co-substrate. Every single deacetylation reaction SIRT3 performs consumes one molecule of NAD⁺.

So what happens when NAD⁺ levels fall?

SIRT3 activity drops proportionally. Mitochondrial proteins become hyperacetylated. ETC function declines. Superoxide rises. SOD2 goes offline. Butyrate oxidation stalls. The colonocyte enters energy crisis.

And what depletes NAD⁺? The very things that define chronic gut dysfunction:

CD38 — an NADase massively upregulated by inflammation. CD38 degrades NAD⁺ thousands of times faster than SIRT3 or any other sirtuin can use it. In chronic inflammation, CD38 expression rises dramatically in immune cells that infiltrate the gut mucosa. One study showed CD38 increases 2–3x with aging alone — and inflammation accelerates this further. This single enzyme may be the dominant driver of NAD⁺ depletion in the chronically inflamed gut.

PARP1 — activated by DNA damage (which superoxide from failing mitochondria causes). Each PARP1 activation event consumes massive amounts of NAD⁺. In an already stressed colonocyte, PARP1 and SIRT3 are competing for a shrinking NAD⁺ pool — and PARP1 has a much higher binding affinity. PARP1 wins. SIRT3 loses.

NAMPT suppression — NAMPT is the rate-limiting enzyme that recycles nicotinamide back into NAD⁺ through the salvage pathway. Chronic inflammation, stress, and aging all suppress NAMPT expression. So NAD⁺ is being consumed faster (by CD38 and PARP1) while simultaneously being produced slower (by suppressed NAMPT).

The result: a progressive, self-reinforcing collapse of SIRT3 activity inside colonocyte mitochondria.

How SIRT3 failure drives the dysbiosis loop

This is where it connects to everything you’ve been told about your microbiome. When SIRT3 drops and butyrate oxidation fails, the colonocyte can no longer consume oxygen efficiently. Oxygen that should be used for mitochondrial respiration instead diffuses into the colonic lumen. The lumen shifts from deeply hypoxic (<1% O₂) to a relatively oxygenated environment.

That single shift changes everything ecologically:

Obligate anaerobes — Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale — are oxygen-sensitive. They decline. Facultative anaerobes — E. coli, Klebsiella, Enterococcus, and sulfate-reducing bacteria like Desulfovibrio — can tolerate oxygen. They expand.

This is what a stool test calls “dysbiosis.” But it’s not a microbial infection. It’s an ecological consequence of host mitochondrial failure — mediated significantly by loss of SIRT3 activity.

And the loop deepens: sulfate-reducing bacteria produce hydrogen sulfide, which directly inhibits Complex IV of the electron transport chain. Proteobacterial expansion increases LPS exposure, driving more NF-κB activation, more inflammation, more CD38 expression, more NAD⁺ depletion, less SIRT3 activity.

The bacteria didn’t cause the dysfunction. The dysfunction created the environment that selected for those bacteria. And those bacteria now make recovery harder — but they’re still not the root cause.

Why this explains treatment failure

This framework explains why so many interventions fail or produce only temporary results:

Probiotics fail because you’re introducing organisms into an oxygenated, inflamed lumen that can’t support them. The terrain is hostile. They pass through.

Antimicrobials reduce pathobionts temporarily, but the oxygen gradient is still broken because SIRT3 is still suppressed and butyrate oxidation is still impaired. The ecology rebounds to dysbiosis within weeks.

Fiber and prebiotics backfire because butyrate is produced but can’t be oxidized. The substrate arrives, but the mitochondrial machinery — which SIRT3 maintains — can’t process it.

Butyrate supplements don’t work for the same reason. The fuel is there. The engine is broken.

Even NAD⁺ precursors (niacinamide, NR, NMN) may underperform if CD38 activity isn’t addressed first. You’re pouring NAD⁺ into a system that’s degrading it faster than you can supply it.

The common thread: every intervention targets downstream effects while the upstream SIRT3–NAD⁺ axis remains broken.

What this means for recovery

True recovery from chronic gut dysfunction requires restoring SIRT3 activity in colonocyte mitochondria. That means:

Rebuilding the NAD⁺ pool — but strategically. Addressing CD38 overexpression (flavonoids like apigenin and quercetin have shown CD38 inhibitory activity in research). Supporting NAMPT activity. Reducing PARP1 hyperactivation by lowering oxidative stress and DNA damage.

Supporting electron transport chain cofactors — riboflavin (FAD for Complex II), CoQ10 (electron carrier), and the B vitamins that feed the TCA cycle.

Reducing mitochondrial toxic load — lowering H₂S burden from sulfate-reducing bacteria, calming NF-κB-driven inflammation, restoring PPAR-γ signaling.

And only then — once colonocyte mitochondrial capacity shows evidence of recovery — reintroducing fermentable substrate to rebuild butyrate-producing ecology.

The sequence matters. Capacity before substrate. Mitochondria before microbiome. SIRT3 before everything.

The bigger picture

SIRT3 is not a supplement target. It’s not something you can buy in a bottle. It’s an indicator of mitochondrial health — a readout of whether the NAD⁺ economy inside your cells is functional enough to maintain the protein quality control that energy production depends on.

When I look at chronic gut dysfunction, I don’t see a bacterial problem. I see an energy problem. A colonocyte that has lost the mitochondrial capacity to maintain the ecological conditions that a healthy microbiome requires. And at the center of that capacity sits SIRT3 — quietly governing whether the electron transport chain runs, whether superoxide gets cleared, whether butyrate gets burned, whether oxygen stays where it belongs.

Fix the mitochondria. Fix the ecology. Fix the gut.

The order has always been the answer.

— Mohammed Attallah

I write about the mechanistic systems underneath gut microbiome ecology, mitochondrial dysfunction, NAD⁺ metabolism, and host-microbe energetics — the layer most protocols never reach.

Substack: @mohammedattallah

Medium: @mattallah922

References

Ahn BH, et al. “A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis.” PNAS (2008). https://www.pnas.org/doi/10.1073/pnas.0803790105

Nogueiras R, et al. “Sirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism.” Physiological Reviews (2012). https://pmc.ncbi.nlm.nih.gov/articles/PMC3746174/

Ansari A, et al. “Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease.” Aging Cell (2017). https://pmc.ncbi.nlm.nih.gov/articles/PMC5242307/

Camacho-Pereira J, et al. “CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism.” Cell Metabolism (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC4911708/

Zeidler JD, et al. “The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.” American Journal of Physiology (2022). https://journals.physiology.org/.../ajpcell.00451.2021

Galli U, et al. “NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.” Frontiers in Oncology (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC7096376/

Xie L, et al. “Nicotinamide phosphoribosyltransferase in NAD⁺ metabolism: physiological and pathophysiological implications.” (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12332177/

Piccolo BD, et al. “Crosstalk between butyrate oxidation in colonocyte and butyrate-producing bacteria.” iScience (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11416512/

Rivière A, et al. “Butyrate and the Fine-Tuning of Colonic Homeostasis: Implication for Inflammatory Bowel Diseases.” Int. J. Mol. Sci. (2021). https://www.mdpi.com/1422-0067/22/6/3061

Scanlan PD, et al. “Culture-independent analysis of desulfovibrios in the human distal colon.” FEMS Microbiology Ecology (2009). https://academic.oup.com/femsec/article/69/2/213/630957

Escande C, et al. “Apigenin: a natural molecule at the intersection of sleep and aging.” Frontiers in Nutrition (2024). https://www.frontiersin.org/.../fnut.2024.1359176/full

Hirschey MD, et al. “SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.” Nature (2010). Referenced via https://pmc.ncbi.nlm.nih.gov/articles/PMC5242307/

Schlicker C, et al. “Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5.” J. Mol. Biol. (2008). Referenced via https://pmc.ncbi.nlm.nih.gov/articles/PMC5242307/